Lawrenceville-based immunotherapy and vaccine company Celsion Corp. has named a new CEO and president, it announced Tuesday.
Celsion said in a news release that Dr. Corinne Le Goff, an experienced biopharmaceutical leader, has been appointed CEO, president and a director, effective Monday. The former CEO and president, Michael H. Tardugno, will remain executive chairman of the board of directors.
“On behalf of the board of directors and the entire Celsion team, I would like to warmly welcome Corinne to Celsion,” Tardugno said in a prepared statement. “She adds tremendous depth of knowledge and joins us at a key inflection point in our evolution, as we work to rapidly advance our GEN-1 program for the treatment of advanced-stage ovarian cancer and build a proprietary vaccine platform based on our Placcine technology.
“Corinne’s skills and expertise in development and commercialization of therapeutics in oncology and immunology make her uniquely qualified to lead us on the next stage of growth. We look forward to her astute guidance.”
Le Goff most recently served as chief commercial officer of Moderna, where she was responsible for developing the global presence and capabilities necessary to ensure the global distribution of that company’s COVID-19 vaccine. She has also worked in executive roles with Amgen and Roche France.
“I am thrilled and honored to join as president and CEO of Celsion at this pivotal point for the company,” she said in a statement. “Celsion has an impressive portfolio of assets that address substantial unmet needs in the current vaccine and oncology landscapes. I look forward to working together with my new colleagues and the board to realize upon the tremendous opportunities and efficiently advance these life-improving solutions for patients through clinical development, regulatory approval and commercialization.”
